In the monthly segment Silver Notes, Nicole Watson from Phoenix Home Care and Hospice talks about the importance of keeping ...

A recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and ...

Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

February is National Heart Health Month, which aims to raise awareness and encourage conversation about heart issues, ...

Teva Pharma Industries Ltd ADR, Allergan PLC, Johnson & Johnson, CVS Health Corp. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

A new study suggests that certain substances in the blood may help identify people with a type of irregular heartbeat called ...

First used in 1785, this century-old medication is now emerging as a modern solution with significant healthcare benefits ...

Using a most cost-effective drug to treat some of the most common and dangerous heart conditions could save the NHS a ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure.